BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Altun E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol. 2009;16:897-905. [PMID: 19375360 DOI: 10.1016/j.acra.2009.01.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Emond S, Brunelle F. Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions. Pediatr Radiol 2011;41:1401-6. [DOI: 10.1007/s00247-011-2167-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
2 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018;69:136-50. [PMID: 29706252 DOI: 10.1016/j.carj.2017.11.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
3 Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. AJNR Am J Neuroradiol 2016;37:1192-8. [PMID: 26659341 DOI: 10.3174/ajnr.A4615] [Cited by in Crossref: 218] [Cited by in F6Publishing: 68] [Article Influence: 36.3] [Reference Citation Analysis]
4 Wagner M, Schilling R, Doeblin P, Huppertz A, Luhur R, Schwenke C, Maurer M, Hamm B, Taupitz M, Durmus T. Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine. Eur Radiol 2013;23:108-14. [DOI: 10.1007/s00330-012-2563-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
5 de Campos RO, Heredia V, Ramalho M, De Toni MS, Lugo-Somolinos A, Fuller ER, Semelka RC. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations. AJR Am J Roentgenol. 2011;196:545-552. [PMID: 21343495 DOI: 10.2214/ajr.10.4500] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
6 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
7 Durmus T, Schilling R, Doeblin P, Huppertz A, Hamm B, Taupitz M, Wagner M. Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine. Invest Radiol 2012;47:183-8. [PMID: 22183078 DOI: 10.1097/RLI.0b013e318236e354] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
8 Louie A. Multimodality imaging probes: design and challenges. Chem Rev 2010;110:3146-95. [PMID: 20225900 DOI: 10.1021/cr9003538] [Cited by in Crossref: 789] [Cited by in F6Publishing: 662] [Article Influence: 71.7] [Reference Citation Analysis]
9 Semelka RC, Commander CW, Jay M, Burke LM, Ramalho M. Presumed Gadolinium Toxicity in Subjects With Normal Renal Function: A Report of 4 Cases. Invest Radiol 2016;51:661-5. [DOI: 10.1097/rli.0000000000000318] [Cited by in Crossref: 52] [Cited by in F6Publishing: 16] [Article Influence: 10.4] [Reference Citation Analysis]
10 Ramalho J, Castillo M, Alobaidy M, Nunes RH, Ramalho M, Dale BM, Semelka RC. High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear Gadolinium-based Contrast Agents. Radiology 2015;276:836-44. [DOI: 10.1148/radiol.2015150872] [Cited by in Crossref: 170] [Cited by in F6Publishing: 147] [Article Influence: 28.3] [Reference Citation Analysis]
11 Wildgruber M, Stadlbauer T, Rasper M, Hapfelmeier A, Zelger O, Eckstein HH, Halle M, Rummeny EJ, Huber AM. Single-dose gadobutrol in comparison with single-dose gadobenate dimeglumine for magnetic resonance imaging of chronic myocardial infarction at 3 T. Invest Radiol 2014;49:728-34. [PMID: 24872002 DOI: 10.1097/RLI.0000000000000076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
12 Cowell GW, Reid AW, Roditi GH. Changing trends in a decade of vascular radiology-the impact of technical developments of non-invasive techniques on vascular imaging. Insights Imaging 2012;3:495-504. [PMID: 22865510 DOI: 10.1007/s13244-012-0188-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Ai T, Goerner F, Patel N, Trelles M, Wu G, Li X, Runge VM. Contrast Dose, Temporal Footprint, and Spatial Resolution Tradeoffs in Dynamic Contrast-Enhanced MRA Performed in a Porcine Model of a Carotid Aneurysm: . Journal of Computer Assisted Tomography 2013;37:105-10. [DOI: 10.1097/rct.0b013e318276fc92] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Semelka RC, Ramalho M, Jay M. Summary of special issue on gadolinium bioeffects and toxicity with a look to the future. Magn Reson Imaging 2016;34:1399-401. [PMID: 27639920 DOI: 10.1016/j.mri.2016.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
15 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
16 Haemel AK, Sadowski EA, Shafer MM, Djamali A. Update on nephrogenic systemic fibrosis: are we making progress?: Update on nephrogenic systemic fibrosis. International Journal of Dermatology 2011;50:659-66. [DOI: 10.1111/j.1365-4632.2010.04851.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
17 Hoelter P, Lang S, Weibart M, Schmidt M, Knott MFX, Engelhorn T, Essig M, Kloska S, Doerfler A. Prospective intraindividual comparison of gadoterate and gadobutrol for cervical and intracranial contrast-enhanced magnetic resonance angiography. Neuroradiology 2017;59:1233-9. [PMID: 28913611 DOI: 10.1007/s00234-017-1922-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
18 Altun E, Martin DR, Wertman R, Lugo-somolinos A, Fuller ER, Semelka RC. Nephrogenic Systemic Fibrosis: Change in Incidence Following a Switch in Gadolinium Agents and Adoption of a Gadolinium Policy—Report from Two U.S. Universities. Radiology 2009;253:689-96. [DOI: 10.1148/radiol.2533090649] [Cited by in Crossref: 112] [Cited by in F6Publishing: 73] [Article Influence: 9.3] [Reference Citation Analysis]
19 Foley WD, Stonely T. CT Angiography of the Lower Extremities. Radiologic Clinics of North America 2010;48:367-96. [DOI: 10.1016/j.rcl.2010.02.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
20 Braunagel M, Ortner F, Schönermarck U, Habicht A, Schindler A, Stangl M, Strobl FF, Reiser M, Clevert DA, Trumm C, Helck A. Dynamic CTA in Native Kidneys Using a Multiphase CT Protocol-Potential of Significant Reduction of Contrast Medium. Acad Radiol 2018;25:842-9. [PMID: 29545025 DOI: 10.1016/j.acra.2017.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Semelka RC, Hernandes Mde A, Stallings CG, Castillo M. Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study. Magn Reson Imaging 2013;31:96-101. [PMID: 22898688 DOI: 10.1016/j.mri.2012.06.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
22 Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali A, Sadowski EA. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Invest Radiol. 2016;51:701-705. [PMID: 26885631 DOI: 10.1097/rli.0000000000000259] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
23 Bardin T, Richette P. Nephrogenic systemic fibrosis. Current Opinion in Rheumatology 2010;22:54-8. [DOI: 10.1097/bor.0b013e328333bf3d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]